• Mirum Pharmaceuticals acquired Bluejay Therapeutics, adding worldwide rights to brelovitug for hepatitis delta virus.
• The company gained new regulatory approvals, including etexlate for CTX and a tablet formulation of Livmarli.
• These updates expand Mirum's clinical pipeline and product lineup beyond its prior focus areas.

Mirum Pharmaceuticals, traded as NasdaqGM:MIRM, is drawing attention with this mix of pipeline expansion and regulatory progress. The stock trades at $92.29, with a 1 year return of 94.0%, a 3 year return of 286.8%, and a very large 5 year return, which gives investors some context around how the market has previously responded to the company's story.

Recent returns have been more mixed, with a 7 day return of a 12.2% decline and a 30 day return of an 8.5% decline, set against an 18.2% gain year to date. As brelovitug moves through clinical milestones and as etexlate and Livmarli's tablet formulation build commercial experience, many investors will likely be watching how new data and adoption trends influence sentiment around NasdaqGM:MIRM.

Stay updated on the most important news stories for Mirum Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Mirum Pharmaceuticals.

The Bluejay Therapeutics deal and recent approvals give Mirum a broader rare-disease portfolio that extends beyond its existing bile-acid programs. Brelovitug, aimed at hepatitis delta virus, sits in late stage development and adds a liver-focused asset that could complement Livmarli and volixibat if clinical data are supportive. At the same time, etexlate for cerebrotendinous xanthomatosis and a tablet version of Livmarli point to a business that is trying to deepen its commercial reach in defined niches where patient access, dosing convenience, and long-term treatment can matter a lot. Against 2025 revenue of US$521.31 million and a full year net loss of US$23.36 million, investors may see this as Mirum leaning into its rare-disease model, even as it continues to invest heavily in research and development. The recently filed shelf registrations totaling more than US$1.2b, alongside earlier equity financings tied to the Bluejay acquisition, also underline that pipeline build out is being funded in part through potential future share issuances, which is an important piece of the story for existing shareholders to track.

How This Fits Into The Mirum Pharmaceuticals Narrative

• The acquisition of Bluejay and the phase 3 brelovitug program supports the existing narrative around late stage catalysts and a rare-disease focused pipeline that could broaden Mirum’s revenue base over time.
• The reliance on additional equity capacity through large shelf registrations could challenge the earlier narrative emphasis on improving margins if future capital raises dilute shareholders more than expected.
• The approval of etexlate for CTX and a Livmarli tablet formulation, as well as the hepatitis delta program, add product and indication breadth that is not fully reflected in a story that previously centered heavily on Livmarli and PFIC or PSC readouts.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Mirum Pharmaceuticals to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ The two shelf registrations totaling more than US$1.2b, together with prior equity deals, signal that further share issuance is possible, so investors may want to consider the risk of future dilution.
• ⚠️ Execution across multiple late stage programs at once, including brelovitug and ongoing volixibat and Livmarli studies, increases clinical and regulatory complexity, which could affect timelines or outcomes.
• 🎁 The addition of brelovitug and the approvals for etexlate and Livmarli tablets broaden Mirum’s rare-disease footprint and could support more diversified revenue if these products gain traction.
• 🎁 2025 revenue of US$521.31 million with a reduced net loss compared to the prior year, alongside positive operating cash flow guidance in company commentary, points to a business that is scaling while continuing to invest in its pipeline.

What To Watch Going Forward

From here, the key watchpoints are clinical and commercial rather than just headline deal news. Investors will likely focus on upcoming brelovitug readouts in hepatitis delta virus and how regulators respond, since that program came with the Bluejay acquisition. Uptake of etexlate in CTX and physician and patient adoption of the Livmarli tablet formulation will also help show whether Mirum can convert new approvals into durable prescriptions. On the financing side, any use of the large shelf registrations, and the pricing and size of future equity offerings, will be important for assessing dilution. Competitive progress from larger rare-disease and liver-focused peers such as Gilead Sciences, AbbVie, or Vertex Pharmaceuticals will also form part of the backdrop for Mirum’s positioning.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Mirum Pharmaceuticals, head to the community page for Mirum Pharmaceuticals to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.